期刊文献+

氨磺必利与利培酮治疗脑血管病所致精神障碍疗效观察 被引量:4

下载PDF
导出
摘要 目的探讨氨磺必利治疗脑血管病所致精神障碍患者的疗效和安全性。方法将60例脑血管病所致精神障碍患者随机分为2组,每组30例,分别给予氨磺必利与利培酮治疗8周,采用阳性与阴性症状量表(PANSS)、日常生活能力量表(ADL)评定疗效,治疗中出现的症状量表(TESS)评定不良反应。结果治疗8周后,氨磺必利组有效率93.3%,利培酮组有效率90.0%,2组疗效比较差异无统计学意义(P>0.05);治疗2周末起,PANSS总分和各因子分较治疗前均显著下降(P<0.05或0.01),且随着治疗的持续进行各分值继续下降;2组间同期比较无显著性差异(P均>0.05);2组不良反应均较少、较轻,氨磺必利组主要表现为失眠、恶心、头晕、静坐不能等;利培酮组主要表现为恶心、嗜睡、EPS(肌强直、静坐不能、震颤)、直立性低血压、心电图异常等。结论氨磺必利与利培酮治疗脑血管病所致精神障碍患者的疗效相当,安全性高、耐受性好,值得在临床中推广应用。
作者 冯连启
出处 《中国实用神经疾病杂志》 2014年第18期48-50,共3页 Chinese Journal of Practical Nervous Diseases
  • 相关文献

参考文献3

二级参考文献35

  • 1陈晋东,赵靖平,李乐华,国效峰,吴仁容,翟金国,王传跃,谢世平,高成阁,丁瑛,陈远光.阿立哌唑治疗精神分裂症的多中心随机双盲对照试验[J].中国新药与临床杂志,2005,24(11):845-848. 被引量:65
  • 2叶翠薇,潘大津,倪小娟,潘君玲,朱桂东.阿立哌唑与奥氮平治疗精神分裂症的对照研究[J].现代中西医结合杂志,2005,14(24):3199-3200. 被引量:8
  • 3吴文源,耿林,陆峥,张耀祖,李春波,刘德英,沈昭在,穆娟,金宇红,陈晓明,刘正福,艾海提.旅途精神病的综合因素分析[J].中华精神科杂志,1997,30(2):95-99. 被引量:15
  • 4SERRETTI A,De RONCHI D,LORENZI C,et al.New antipsychotics and schizophrenia:a review on efficacy and side effects[J].Curr Med Chem,2004,11 (3):343-358.
  • 5DEAN B,SCARR E.Antipsychotic drugs:evolving mechanisms of action with improved therapeutic benefits[J].Curr Drug Targets CNS Neurol Disord,2004,3(3):217-225.
  • 6HOULTRAM B,SCANLAN M.Care maps:atypical antipsychotics.Introduction[J].Nurs Stand,2004,18 (36):42-44.
  • 7VOLAVKA J,CZOBOR P,SHEITMAN B,et al.Clozapine,olanzapine,risperidone,and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder[J].Am J Psychiatry,2002,159 (2):255-262.
  • 8BITTER I,DOSSENBACH MR,BROOK S,et al.Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia[J].Prog Neuropsychopharmacol Biol Psychiatry,2004,28(1):173-180.
  • 9JESTE DV,BARAK Y,MADHUSOODANAN S,et al.International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia[J].Am J Geriatr Psychiatry,2003,11 (6):638-647.
  • 10MULLEN J,JIBSON MD,SWEITZER D.A comparison of the relative safety,efficacy,and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders:the quetiapine experience with safety and tolerability(QUEST) study[J].Clin Ther,2001,23(11):1839-1854.

共引文献62

同被引文献54

  • 1LeeRK,GrahamCA,YeungJH,etal.OccultpneumothoracesinChinesepatientswithsignificantbluntchesttrauma:radiologicalclassificationandproposedclinicalsignificance[J].Injury,2012,43(12):133-135.
  • 2LeMoigneP,RagouetP.Scienceasinstrumentation.Thecaseforpsychiatricratingscales[J].Scientometrics,2012,93(2):165-170.
  • 3刘其春.探讨奎硫平与氟哌啶治疗脑血管病所致精神障碍的临床疗效[J].延边医学,2015,6(5):11-12.
  • 4Carta MG, Pala AN, Finco G, et al. Depression and cerebrovascular dis- ease:could vortioxetine represent a valid treatment option[ J] .? Clin Pract Epidemiol Ment Health,2015 ;11 (4) :144-9.
  • 5Chan MC, Chong CS, Wu AY,et al. Antipsychotics and risk of cerebrovas- cnlar events in treatment of behavioural and psychological symptoms of dementia in Hong Kong. a hospital-based, retrospective, cohort study [ J ]. Int J Geriatr Psychiatry ,2010 ;25 (4) :362-70.
  • 6Nagasawa J, Kiyozaka T, Ikeda K,et al. Prevalence and clinicoradiologal analyses of patients with Alzheimer disease coexisting multiple microb- leeds[ J ]. J Stroke Cerebrovasc Dis,2014 ;23 (9) :2444-9.
  • 7Newman GC, Bang H, Hussain SI, et al. Association of diabetes, homocysteine, and HDL with cognition and disability after stroke [J]. Neurology, 2007, 69 (22): 2054-2062.
  • 8安慧,杜伟国,郭万红,等.心理干预对脑血管病伴精神障碍患者的影响[J].现代诊断与治疗,2012,21(11):204—206.
  • 9Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments [ J ]. Lancet Neurol, 2008, 7 (3) : 246 - 255.
  • 10Kang EK, Baek MJ, Kim S. Non - invasive cortical stimulation improves poststroke attention decline [ J]. Restor Neurol Neurosci, 2014, 12 (6): 645-650.

引证文献4

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部